269 related articles for article (PubMed ID: 32617743)
21. Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.
Yuzawa S; Nishihara H; Yamaguchi S; Mohri H; Wang L; Kimura T; Tsuda M; Tanino M; Kobayashi H; Terasaka S; Houkin K; Sato N; Tanaka S
Mod Pathol; 2016 Jul; 29(7):708-16. PubMed ID: 27102344
[TBL] [Abstract][Full Text] [Related]
22. Classification of meningiomas-advances and controversies.
Harter PN; Braun Y; Plate KH
Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S2. PubMed ID: 28595423
[TBL] [Abstract][Full Text] [Related]
23. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.
Choudhury A; Magill ST; Eaton CD; Prager BC; Chen WC; Cady MA; Seo K; Lucas CG; Casey-Clyde TJ; Vasudevan HN; Liu SJ; Villanueva-Meyer JE; Lam TC; Pu JK; Li LF; Leung GK; Swaney DL; Zhang MY; Chan JW; Qiu Z; Martin MV; Susko MS; Braunstein SE; Bush NAO; Schulte JD; Butowski N; Sneed PK; Berger MS; Krogan NJ; Perry A; Phillips JJ; Solomon DA; Costello JF; McDermott MW; Rich JN; Raleigh DR
Nat Genet; 2022 May; 54(5):649-659. PubMed ID: 35534562
[TBL] [Abstract][Full Text] [Related]
24. Histological classification and molecular genetics of meningiomas.
Riemenschneider MJ; Perry A; Reifenberger G
Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of DNA methylation-based integrated classification of histologically defined grade 2 meningiomas.
Ehret F; Perez E; Teichmann D; Meier S; Geiler C; Zeus C; Franke H; Roohani S; Wasilewski D; Onken J; Vajkoczy P; Schweizer L; Kaul D; Capper D
Acta Neuropathol Commun; 2024 May; 12(1):74. PubMed ID: 38720399
[TBL] [Abstract][Full Text] [Related]
26. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation.
Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M
Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274
[TBL] [Abstract][Full Text] [Related]
27. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
28. Whole-genome sequencing identifies new genetic alterations in meningiomas.
Tang M; Wei H; Han L; Deng J; Wang Y; Yang M; Tang Y; Guo G; Zhou L; Tong A
Oncotarget; 2017 Mar; 8(10):17070-17080. PubMed ID: 28177878
[TBL] [Abstract][Full Text] [Related]
29. Innovative treatments for meningiomas.
Graillon T; Tabouret E; Salgues B; Horowitz T; Padovani L; Appay R; Farah K; Dufour H; Régis J; Guedj E; Barlier A; Chinot O
Rev Neurol (Paris); 2023 Jun; 179(5):449-463. PubMed ID: 36959063
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
[TBL] [Abstract][Full Text] [Related]
31. Meningioma pathology, genetics, and biology.
Lamszus K
J Neuropathol Exp Neurol; 2004 Apr; 63(4):275-86. PubMed ID: 15099018
[TBL] [Abstract][Full Text] [Related]
32. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
[TBL] [Abstract][Full Text] [Related]
33. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.
Choy W; Kim W; Nagasawa D; Stramotas S; Yew A; Gopen Q; Parsa AT; Yang I
Neurosurg Focus; 2011 May; 30(5):E6. PubMed ID: 21529177
[TBL] [Abstract][Full Text] [Related]
34. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of meningiomas: from basic research to potential clinical applications.
Simon M; Boström JP; Hartmann C
Neurosurgery; 2007 May; 60(5):787-98; discussion 787-98. PubMed ID: 17460514
[TBL] [Abstract][Full Text] [Related]
36. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
[TBL] [Abstract][Full Text] [Related]
37. Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Clark VE; Harmancı AS; Bai H; Youngblood MW; Lee TI; Baranoski JF; Ercan-Sencicek AG; Abraham BJ; Weintraub AS; Hnisz D; Simon M; Krischek B; Erson-Omay EZ; Henegariu O; Carrión-Grant G; Mishra-Gorur K; Durán D; Goldmann JE; Schramm J; Goldbrunner R; Piepmeier JM; Vortmeyer AO; Günel JM; Bilgüvar K; Yasuno K; Young RA; Günel M
Nat Genet; 2016 Oct; 48(10):1253-9. PubMed ID: 27548314
[TBL] [Abstract][Full Text] [Related]
38. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
39. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.
Kalamarides M; Niwa-Kawakita M; Leblois H; Abramowski V; Perricaudet M; Janin A; Thomas G; Gutmann DH; Giovannini M
Genes Dev; 2002 May; 16(9):1060-5. PubMed ID: 12000789
[TBL] [Abstract][Full Text] [Related]
40. Molecular genetic features of meningiomas.
Makashova ES; Lasunin NV; Galkin MV; Zolotova SV; Karandasheva KO; Golanov AV
Zh Vopr Neirokhir Im N N Burdenko; 2023; 87(4):101-106. PubMed ID: 37650282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
